SCHEMBL13638135

SCHEMBL13638135

CC(=O)SCCC(=O)NC1CCCCCCCCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ HPGD P15428 6/20 0.54
▸ TSHR P16473 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.50
▸ HDAC3 O15379 2/20 0.49
▸ HDAC1 Q13547 2/20 0.49
▸ HDAC2 Q92769 2/20 0.49
▸ HDAC10 Q969S8 2/20 0.49
▸ HDAC11 Q96DB2 2/20 0.49
▸ HDAC8 Q9BY41 2/20 0.49
▸ HDAC6 Q9UBN7 2/20 0.49
▸ NCOR2 Q9Y618 1/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ SIGMAR1 Q99720 1/20 0.47
▸ LMNA P02545 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638132 0.83 EPHX1 (0.41) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL10982270 0.82 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1HPGDTSHRNPSR1
SCHEMBL31532555 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL21340181 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL14110289 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL18613033 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL10085163 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL10078381 0.82 NPSR1 (0.53) SMN1; SMN2ALDH1A1HPGDNPSR1EPHX1
SCHEMBL9516460 0.82 ALDH1A1 (0.69) SMN1; SMN2ALDH1A1HPGDTSHRNPSR1
SCHEMBL10587847 0.79 ALDH1A1 (0.83) SMN1; SMN2ALDH1A1HPGDNPSR1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090281066-A1 Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281066-A1 Treatment of proliferative disorders with amino-substituted (E)-2,6- dialkoxystyryl 4-substituted benzylsulfones CCNY, CCND2, ETV6 SMN1; SMN2 3461/4885ALDH1A1 1156/4885HPGD 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback